Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14342613 | 0.86 | POLB (0.47) | HSD11B1POLBCACNA1GCACNA1HHTT | |
| SCHEMBL3928873 | 0.82 | NPC1 (0.59) | POLBEPHX2CACNA1GCACNA1H | |
| SCHEMBL13602146 | 0.79 | NPSR1 (0.70) | HSD11B1EPHX2HSD17B10 | |
| SCHEMBL7306852 | 0.75 | POLB (0.83) | POLBL3MBTL1CACNA1GCACNA1HHTT | |
| SCHEMBL17117487 | 0.75 | POLB (0.61) | POLBCACNA1GCACNA1H | |
| SCHEMBL13602142 | 0.75 | HSD11B1 (0.51) | HSD11B1EPHX2HSD17B10L3MBTL1 | |
| SCHEMBL26111732 | 0.74 | POLB (0.59) | POLBCACNA1GCACNA1H | |
| SCHEMBL26113012 | 0.74 | POLB (0.59) | POLBCACNA1GCACNA1H | |
| SCHEMBL26107974 | 0.74 | POLB (0.59) | POLBCACNA1GCACNA1H | |
| SCHEMBL3928254 | 0.73 | L3MBTL1 (0.59) | HSD11B1EPHX2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | claimed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | claimed |
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306048-A1 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HSD11B1, HSD3B1, CES1 | HSD11B1 1/4885POLB 1203/4885EPHX2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.